Erin Newburn, PhD
Director, Field Applications Scientist
Wednesday, OCT 13 | 2:45 PM BST
Maximizing Immuno-Oncology Biomarker Discovery with the Universal Cancer Immunogenomics Platform ImmunoID NeXT
- To enable the identification of composite biomarkers that combine tumor- and immune-related information from both DNA and RNA, we have developed the Personalis NeXT platform
- By utilizing the expansive feature set, individual analytes can be combined to construct composite biomarker scores that correlate with immunotherapy response.
- In a cohort of 51 late-stage melanoma patients, the integration of neoantigen burden, HLA LOH, and APM mutational data formed a neoantigen-based composite neoantigen (NEOPS) that more accurately predicted response to checkpoint blockade than other markers such as TMB.
- The platform has been analytically validated and optimized for use with limited FFPE tissue samples, making it ideal for both research and clinical applications.